Key result
High admission NT-proBNP linked to ~169% higher 1-year mortality in hospitalized COVID-19 patients.
Why the study?
Data on the association between baseline NT-proBNP levels and long-term prognosis in COVID-19 patients were scarce.
Do high baseline age-adjusted NT-proBNP levels predict worse short- and long-term mortality in hospitalized COVID-19 patients?
Observational (n=499)
No
Do high baseline age-adjusted NT-proBNP levels predict worse short- and long-term mortality in hospitalized COVID-19 patients?
High age-adjusted NT-proBNP levels at hospital admission for COVID-19 independently predict both in-hospital and one-year mortality.
Elevated age-adjusted NT-proBNP flags higher 1-year mortality in COVID-19; leaves open whether measurement refines post-discharge risk stratification.
BACKGROUND: Up to 20% of COVID-19 patients can suffer COVID-19-related myocardial injury. Elevated cardiac biomarkers, such as hs-cTnT and NT-proBNP, have been related to worse short-term prognosis. However, data on NT-proBNP and long-term prognosis are scarce. We have evaluated the potential association of baseline age-adjusted NT-proBNP levels and outcomes at one-year follow-up in COVID-19 patients. METHODS: This was a single-center prospective study of 499 COVID-19 patients in whom NT-proBNP was assessed at hospital admission. NT-proBNP levels were age-adjusted and patients were classified as high or low NT-proBNP. Clinical and demographic characteristics, comorbidities, laboratory results, and in-hospital complications and mortality were compared between the two groups. Survivors of the acute phase of COVID-19 were followed up for one year from admission to detect readmissions and mortality. RESULTS: The 68 patients with high NT-proBNP levels at hospital admission were older, with more cardiovascular risk factors, cardiovascular disease, comorbidities, myocardial injury, and higher levels of inflammatory markers than patients with low NT-proBNP levels. They also had more in-hospital complications and a higher acute-phase mortality rate (60.3% vs. 10.2%, p < 0.001). High NT-proBNP levels were an independent marker of death during hospitalization (HR 1.95; CI 1.07-3.52). At one-year follow-up, high NT-proBNP levels were independently associated with mortality (HR 2.69; CI 1.47-4.89). Among survivors of the acute phase of COVID-19, there were no differences in hospital readmissions between those with high vs. low NT-proBNP levels, but survivors with high baseline NT-proBNP levels showed a higher 1-year mortality rate (7.4% vs. 1.3%, p = 0.018). CONCLUSIONS: High age-adjusted NT-proBNP levels at the time of hospital admission for COVID-19 are associated with poor short and long-term prognosis. High NT-proBNP seems also to be related to worse prognosis in survivors of the acute phase of COVID-19. A closer follow-up on these patients may be crucial.
No takes yet. Share an insight, caveat, or question.
Mojón-Álvarez et al. (2024) conducted an observational in COVID-19 (n=499). High age-adjusted NT-proBNP levels vs. Low age-adjusted NT-proBNP levels was evaluated on 1-year mortality (HR 2.69, 95% CI 1.47-4.89, p=0.001). High age-adjusted NT-proBNP levels at hospital admission for COVID-19 were independently associated with a significantly increased risk of 1-year mortality (HR 2.69) compared to low levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: